Acumen Pharmaceuticals (NASDAQ:ABOS) & VectivBio (NASDAQ:VECT) Head-To-Head Survey

VectivBio (NASDAQ:VECT) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership and dividends.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for VectivBio and Acumen Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VectivBio	0	0	0	0	N/A
Acumen Pharmaceuticals	0	0	4	0	3.00

Acumen Pharmaceuticals has a consensus target price of $12.00, indicating a potential upside of 403.14%. Given Acumen Pharmaceuticals’ higher probable upside, analysts clearly believe Acumen Pharmaceuticals is more favorable than VectivBio.

Earnings & Valuation

This table compares VectivBio and Acumen Pharmaceuticals’ top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VectivBio	$27.34 million	N/A	-$93.74 million	N/A	N/A
Acumen Pharmaceuticals	N/A	N/A	-$52.37 million	($1.06)	-2.25

Acumen Pharmaceuticals has lower revenue, but higher earnings than VectivBio.

Institutional & Insider Ownership

71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. 9.7% of VectivBio shares are owned by company insiders. Comparatively, 7.1% of Acumen Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares VectivBio and Acumen Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
VectivBio	N/A	N/A	N/A
Acumen Pharmaceuticals	N/A	-22.88%	-20.82%

About VectivBio

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). VectivBio Holding AG was incorporated in 2019 and is headquartered in Basel, Switzerland. As of June 29, 2023, VectivBio Holding AG operates as a subsidiary of Ironwood Pharmaceuticals, Inc.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.